Common questions about Kiovig (FAQ)
Q: Is Kiovig the same as other IVIG products?
A: Kiovig is classified as a Human Normal Immunoglobulin (IVIg) product, meaning it contains the same active component: high-purity Immunoglobulin G (IgG) with all four subclasses. According to official product information, it shares the same primary purpose and mechanism of action as other IVIg products. However, different IVIg products may have variations in their non-active ingredients (excipients) and trace components.
Q: How does Kiovig help the immune system?
A: Kiovig works in two primary ways: first, as a replacement therapy, it provides a broad spectrum of protective antibodies that are missing or insufficient in the patient, helping to fight infections. Second, it acts as an immunomodulator, meaning it helps to regulate and balance the immune response when the body's natural defense system is acting abnormally.
Q: How long do the effects of a Kiovig infusion last?
A: The effects of the infusion are monitored to last through the next treatment cycle. For replacement therapy, the dosing is typically scheduled every three to four weeks. This interval is used by healthcare professionals to guide the scheduling of the next dose.
Q: Is a headache after Kiovig treatment normal?
A: Yes, headache is listed as a very common adverse reaction in the official product documents, potentially affecting more than 1 in 10 people. Official product information suggests that the headache may be related to the rate of infusion and should be discussed with the healthcare professional administering the treatment.
Q: Are there any long-term side effects associated with Kiovig use?
A: Official regulatory documents emphasize that patients must be monitored for serious acute risks, such as thromboembolic events (blood clots) and acute renal failure (kidney injury). While these are not generally defined as 'long-term' effects, the administration of Kiovig requires a healthcare professional to perform ongoing caution and monitoring, as specified in official product labeling.
Q: Can elderly patients safely receive Kiovig?
A: Patients of advanced age are noted in official warnings as being at increased risk for serious events like blood clots and acute kidney failure. Official guidance specifies that Kiovig should be administered with caution in patients 65 and older. Administration requires the prescribing physician to consider using the minimum effective dose and a slow infusion rate.
Q: Can people with kidney issues use Kiovig?
A: Patients who have pre-existing renal impairment (kidney issues) can use Kiovig, but they are considered to be at a higher risk of developing acute renal failure. Official guidance requires the patient to be closely monitored during treatment, and the healthcare team administering the medicine should consider using a slow infusion rate.
Q: What kind of research has been done on Kiovig's effectiveness?
A: The effectiveness of Kiovig for its approved uses has been investigated through clinical trials, including randomized controlled trials (RCTs) and long-term studies. This research examined its performance in specific patient populations, such as those with Primary Immunodeficiency (PID) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), providing the evidence base for its official indications.
Q: How does Kiovig affect the body's antibody levels?
A: In patients receiving replacement therapy for antibody deficiencies, Kiovig provides the missing antibodies and acts to increase the patient’s overall Immunoglobulin G (IgG) levels. The prescribing physician will adjust the individual's dosing to try and maintain Immunoglobulin G (IgG) levels above a defined protective trough level before the next scheduled infusion.
Q: What is the expected timeline to start feeling better after Kiovig?
A: For replacement therapy in Primary Immunodeficiency, official data indicates that it can take a period of three to six months after starting therapy for the Immunoglobulin G (IgG) levels in the blood to reach a stable, protective concentration. Clinical studies indicate that the time required to see a stable therapeutic effect varies depending on the medical condition and individual patient response.
Q: What should I do if I miss a scheduled Kiovig appointment?
A: If a dose is missed, regulatory guidance recommends that a healthcare professional be contacted to determine when it should be administered. The physician will then adjust the remaining scheduled treatment cycle accordingly.
Q: Is there any food or drink I should avoid while on Kiovig?
A: Regulatory documents on medicine interactions do not list any specific known interactions with food or alcohol that require avoidance while taking Kiovig. Always review your overall diet, alcohol consumption, and supplement intake with a healthcare professional during therapy.
Q: Is Kiovig used to treat autoimmune diseases generally?
A: Kiovig is officially approved for specific autoimmune and inflammatory disorders. These indications include Primary Immune Thrombocytopenia (ITP), Guillain-Barré syndrome, Kawasaki disease, Multifocal Motor Neuropathy (MMN), and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
Q: What is the risk of getting an infection from Kiovig?
A: As Kiovig is derived from human blood plasma, official documents advise of the theoretical risk of transmitting infectious agents. However, mandatory manufacturing processes include steps designed to reduce the risk of transmitting infectious agents, such as screening donors and methods for viral removal/inactivation.
Q: Why is it important to stay hydrated before a Kiovig infusion?
A: Adequate hydration is a necessary step to help minimize the risk of serious complications, particularly the rare chance of developing a thromboembolic event (a blood clot) or acute renal failure (kidney injury), as noted in the product's safety information.
Q: Is it normal to feel tired the day after a Kiovig treatment?
A: Yes, fatigue is documented in the official safety information as a common adverse reaction, potentially affecting up to 1 in 10 people. This feeling of tiredness or low energy is common and may be experienced by patients during or in the period immediately following the infusion.
Q: Can I drive after receiving a Kiovig infusion?
A: Official information advises that if you experience any adverse reactions that could impair your focus, such as dizziness or fatigue, your ability to drive or operate machines may be affected. Patients who experience adverse reactions such as dizziness or fatigue are advised to refrain from driving or operating machinery until those effects have completely resolved.
Q: Does Kiovig affect fertility or pregnancy?
A: Based on clinical experience with immunoglobulins, no harmful effects on fertility or the course of pregnancy are expected. However, official guidance states that the medicine should only be administered to pregnant or breastfeeding women if there is a clear medical need.
Q: What's the difference between IVIG and SCIG (Subcutaneous Immunoglobulin) formulations?
A: IVIg refers to the medicine being delivered intravenously (into a vein), which is the standard route for all approved uses. SCIG refers to a subcutaneous (under the skin) delivery, which is only a permitted route for replacement therapy in Primary Immunodeficiency syndromes.
Q: Can Kiovig be used for primary immunodeficiency?
A: Yes, the official therapeutic indications state that Kiovig is indicated as replacement therapy for adults and children diagnosed with Primary Immunodeficiency Syndromes (PID). This use provides the patient with the protective antibodies their body cannot produce on its own.
Q: What should I tell my doctor about before starting Kiovig?
A: You should inform your doctor about any past allergic reactions to human immunoglobulins or any severe allergies, especially if you have a known IgA deficiency. It is also important to discuss any history of heart or kidney problems, risk factors for blood clots (like diabetes or high blood pressure), or any recent or planned vaccinations.
Q: What are common patient experiences during a Kiovig infusion?
A: Common experiences during or after the infusion may include general symptoms like headache, chills, fever, nausea, or fatigue. Local reactions at the infusion site, such as mild redness, warmth, or soreness, may also occur. These are usually mild and often relate to the rate of infusion.
Q: How quickly do infusion-related reactions usually start with Kiovig?
A: Most acute adverse reactions typically occur either during the infusion or shortly after it finishes. Official protocol requires patients to be closely monitored throughout the entire infusion and for at least 20 minutes afterward, and up to 60 minutes for first-time treatments or when switching products.
Q: Why is it necessary to monitor kidney function when using Kiovig?
A: Kidney function must be monitored because, very rarely, the infusion can lead to acute renal failure (acute kidney injury), especially in patients with existing risk factors. This monitoring is a clinical requirement intended to help the healthcare team assess the patient's safety profile and ensure kidney function remains adequate during treatment.
Q: Is it normal for the injection/infusion site to be sore after Kiovig?
A: Yes, local infusion site reactions, which include soreness, pain, redness, or swelling, are listed as a common adverse reaction in the official safety documents. These reactions are typically mild or moderate and temporary.
Q: Are there any known issues when switching from another IVIG product to Kiovig?
A: Official safety information notes that adverse reactions may occur more frequently when a patient is switched from one type of immunoglobulin product to another. For this reason, closer monitoring and a longer observation time (up to 60 minutes) after the infusion are recommended when switching products.
